Trial record 1 of 5 for:
Saturn 2 trial
Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis (Saturn-2)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04784091 |
|
Recruitment Status :
Completed
First Posted : March 5, 2021
Last Update Posted : December 2, 2022
|
Sponsor:
Tarsus Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Tarsus Pharmaceuticals, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to compare the safety and efficacy of TP-03, an eyedrop, to its vehicle control for the treatment of blepharitis due to Demodex, a microscopic mite frequently found in human hair follicles.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Blepharitis | Drug: TP-03 Drug: TP-03 Vehicle | Phase 3 |
This Phase 3 study is a randomized, controlled, multicenter, double-masked, parallel trial to compare the safety and efficacy of TP-03 to vehicle control for the treatment of Demodex blepharitis. The primary objective of the study is to assess the safety and efficacy of TP-03, 0.25% compared to its vehicle from Day 1 to Day 43 in adult participants with mild to severe Demodex blepharitis. The primary efficacy endpoint will be cure based upon collarettes. Safety will be determined by assessing adverse effects related to the treatment as well as evaluating any changes in visual acuity, intraocular pressure, slit lamp biomicroscopy, endothelial cell density, hematology, blood chemistry, and urinalysis.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 412 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Active arm: TP-03, 0.25% Control arm: Vehicle of TP-03 |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Masking Description: | Treatment assignment will be unknown to the study participant, investigators and site staff performing study assessments. |
| Primary Purpose: | Treatment |
| Official Title: | Randomized, Controlled, Multicenter, Double-Masked, Parallel, Phase 3 Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis |
| Actual Study Start Date : | April 29, 2021 |
| Actual Primary Completion Date : | May 9, 2022 |
| Actual Study Completion Date : | May 9, 2022 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Active
TP-03, lotilaner ophthalmic solution, 0.25%, administered topically twice a day for approximately 43 days
|
Drug: TP-03
TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day |
|
Placebo Comparator: Control
Vehicle of TP-03 ophthalmic solution, administered topically twice a day for approximately 43 days
|
Drug: TP-03 Vehicle
Vehicle of TP-03 ophthalmic solution, administered twice a day |
Primary Outcome Measures :
- The proportion of participants cured based on their collarette score [ Time Frame: 43 days ]
Secondary Outcome Measures :
- The proportion of participants with their Demodex mites eradicated [ Time Frame: 43 days ]
- The proportion of participants cured based on a composite of collarette score and erythema score [ Time Frame: 43 days ]
- The proportion of participants cured based on erythema score [ Time Frame: 43 days ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Be willing to sign the informed consent and deemed capable of complying with the requirements of the study protocol
- Meet all of the following criteria in at least one eye: Have more than 10 lashes with collarettes present on the upper lid; have at least mild erythema of the upper eyelid margin; have an average Demodex density, upper and lower eyelids combined, of 1.5 or more mites per lash
Exclusion Criteria:
- Have used lid hygiene products within 14 days of Screening or unwilling to forego the use of lid hygiene products during the study
- Have used a prostaglandin analogue to promote eyelash growth within 30 days of Screening or any plans to initiate treatment during the study
- Have used artificial eyelashes or eyelash extensions within 7 days of Screening or be unwilling to forego their use during the study
- Be pregnant or lactating at the time of Screening
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04784091
Locations
Show 21 study locations
Sponsors and Collaborators
Tarsus Pharmaceuticals, Inc.
Investigators
| Principal Investigator: | John Meyer, MD | The Eye Care Institute |
| Responsible Party: | Tarsus Pharmaceuticals, Inc. |
| ClinicalTrials.gov Identifier: | NCT04784091 |
| Other Study ID Numbers: |
TRS-010 |
| First Posted: | March 5, 2021 Key Record Dates |
| Last Update Posted: | December 2, 2022 |
| Last Verified: | November 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Tarsus Pharmaceuticals, Inc.:
|
Demodex |
Additional relevant MeSH terms:
|
Blepharitis Eyelid Diseases Eye Diseases |